Establishment Labs Announces the Appointment of Dr. Dennis Hammond to its Medical Advisory Board

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, is pleased to announce that Dr. Dennis Hammond has joined the company's Medical Advisory Board.

“Dr. Hammond is a thought leader in breast aesthetics and breast reconstruction and we are thrilled that he has agreed to join our team,” said Juan José Chacón Quirós, CEO of Establishment Labs. He added, “Dr. Hammond will play a fundamental role in developing our next generations of Motiva implants, with a focus on increasing the lifetime of these devices, leading to optimal patient satisfaction rates.”

Dr. Hammond is one of the world's most recognised and respected authorities in aesthetic and reconstructive surgery of the breast and has participated in most relevant breast implant studies since 1990. Among his achievements are the development of tissue expander technology for breast reconstruction, the creation of the BodyLogic® evaluation system used for implant sizing in breast augmentation, and the development of SPAIR Mammaplasty, a procedure to reduce scarring in breast reduction and lifting. He also served as the Medical Director for the Contour Profile® Gel (CPG) anatomically shaped cohesive gel breast implant study.

“Establishment Labs is incorporating super-silicones to dramatically increase the durability of breast implants, designing structural improvements to prevent implant rippling and rethinking the device interphase for increased control of the implant position," said Dr. Hammond, "Establishment Labs is at the forefront of innovation and I am excited to contribute to the development of the next generation of breast implants."

Dr. Hammond has co-edited one of the most influential textbooks in plastic surgery, Surgery of the Breast: Principles and Art along with Dr. Scott Spear from Georgetown University in Washington DC. In addition, he has authored numerous book chapters concerning a host of breast related topics in nearly every respected plastic surgery textbook currently in use. He has also written his own single author textbook, Atlas of Aesthetic Breast Surgery, first published in 2009. This best-selling text is currently recognised by serious students of breast surgery as a "how to" guide to successful outcomes. Dr. Hammond has authored many scientific papers, and currently serves as an associate editor for Plastic and Reconstructive Surgery, the main scientific journal for plastic surgeons around the world. He also serves as a reviewer of scientific articles for Aesthetic Plastic Surgery and the Journal of Aesthetic Surgery. Dr. Hammond is a member of and serves on numerous committees for the American Society of Plastic Surgeons (ASPS) as well as for the American Society for Aesthetic Plastic Surgery (ASAPS) and of the prestigious American Association of Plastic Surgeons (AAPS).

The appointment of Dr Hammond strengthens the already very impressive Scientific and Medical Advisory Boards that Establishment Labs have put together.  Dr Hammond joins Dr Scott Spear, Dr Brian Kinney, Dr Robert Langer, Dr Ardeshir Bayat and Dr Hilton Becker, among others, in what we believe is the most impressive collection of professionals working together for any medical aesthetics company.

BodyLogic® and Contour Profile® are registered trademarks of Mentor Worldwide LLC.

Future of Motiva Micro-transponder Secured

JAMM Technologies, LLC announced last week that it has purchased a portfolio of assets from Veriteq Corporation, including its implantable RFID solutions, UDI business and intellectual property. The company also disclosed that it has entered into a long term supply agreement with Establishment Labs to provide implantable micro-transponder technology for their current and next generation family of silicone breast implants.

JAMM Technologies has begun implementing its vision to become an identification and reference platform for implantable medical devices. “All long term implantable devices should have RFID technology to provide key information on the safety and functionality of these devices,” said Randy Geissler, Chief Technology Officer of JAMM Technologies. “The ability for doctors to identify and communicate with implantable medical devices will allow for the development of smart devices that increase both safety and health.”

Juan Jose Chacón Quirós, CEO of Establishment Labs, added, “Implantable RFID technology is one of the most exciting technologies in medical devices. Our agreement with JAMM secures the supply of Q Inside Safety Technology™ and the future development of diagnostic capabilities in biosensors for the next generation of Motiva breast implants.”

There have been over 40,000 implantations of Motiva Implants® with Q Inside Safety Technology™ in the European Union and Japan. Q Inside Safety Technology™ is an FDA cleared and CE approved RFID solution that allows plastic surgeons to connect patients through the MotivaImagine™ App to an electronic passport that contains all the relevant information about the breast implant for increased safety and peace of mind.

We are very pleased that this agreement means Motiva implants will continue to offer Q inside safety technology, providing the highest level of safety for patients.

Motiva's Best in Class Extended Warranty Just Got Better

Establishment Labs, manufacturers of Motiva breast implants, has today announced that their extended warranty programme has been improved to provide better protection for all patients with Motiva implants, at a lower price.

In 2010 Establishment Labs introduced their extended warranty programme which was backed by an insurance policy underwritten by Lloyds of London, one of the world's best known insurance companies.  This warranty programme protected patients who had Motiva implants with Qinside Safety technology, covering the two most common breast augmentation related complications, rupture and capsular contracture (Baker grades III and IV).  The first year of cover was provided free of charge and patients then had the option to extend their cover for up to 10 years at a cost of around £40 per implant per year. 

Under the original warranty, patients affected by either of these complications were able to claim up to £1500 per affected implant.  This benefit is over and above Motiva's Always Confident Warranty which is a lifetime guarantee providing for free replacement implants in case of implant rupture and their Product Replacement Guarantee which provides free replacement implants should the patient experience a Baker grade III or IV capsular contracture within 10 years of implantation.  This level of patient protection is unmatched in the breast implant industry.

Establishment Labs have now increased their levels of patient protection by putting in place a product liability policy worth $15,000,000 underwritten by one of America's largest insurers, CNA. Alongside this, they have also developed an improved extended warranty programme which will provide cover for all patients with Motiva implants rather than only those with Qinside Safety Technology.

The extended warranty programme is now in two parts, the 2y programme for implants without Qinside and the 5y programme for implants with the Qinside Safety Technology. As with the original extended warranty, patients are protected against implant rupture and capsular contracture Baker grades III and IV with the 5y programme the first year of coverage is once again free of charge .

Under the 2y programme the patient has the option to extend their cover for 2 years at a cost of just £100.  In the event of either implant rupture or grade III/IV capsular contracture during the period of cover, Establishment Labs will contribute £1000 per affected implant towards the cost of the reoperation.

Under the 5y programme, the patient has the option to extend their cover for another 4 years at a cost of just £200 (making 5 years in total).  In the event of either implant rupture or grade III/IV capsular contracture during the period of cover, Establishment Labs will contribute £2500 per affected implant towards the cost of the reoperation.

As with the original extended warranty, Motiva's Always Confident Warranty and Product Replacement Guarantee also apply.

In order to qualify for Motiva's extended warranties, patients must register their implants either at Motivaimplants.com or via the mobile app which is available in both the app store and Google Play store free of charge.